Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Feb 28

PMID 35222439

Authors

Vera S Donnenberg

Patrick L Wagner

James D Luketich

David L Bartlett

Albert D Donnenberg

Affiliations

Soon will be listed here.

Abstract

Metastasis to the pleural and peritoneal cavities is a common terminal pathway for a wide variety of cancers. This article explores how these unique environments both promote aggressive tumor behavior and suppresses anti-tumor immunity, and ways in which local delivery of protein therapeutics can leverage the contained nature of these spaces to a therapeutic advantage, achieving high intra-cavital concentrations while minimizing systemic toxicity.

Citing Articles

A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting.

Donnenberg V, Luketich J, Popov B, Bartlett D, Donnenberg A Front Immunol. 2024; 15:1404373.

PMID: 39114667 PMC: 11303180. DOI: 10.3389/fimmu.2024.1404373.

Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.

Dadgar N, Sherry C, Zimmerman J, Park H, Lewis C, Donnenberg A J Transl Med. 2024; 22(1):402.

PMID: 38689325 PMC: 11061933. DOI: 10.1186/s12967-024-05205-8.

Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment.

Lewis C, Dadgar N, Yellin S, Donnenberg V, Donnenberg A, Bartlett D Cancers (Basel). 2023; 15(20).

PMID: 37894473 PMC: 10605802. DOI: 10.3390/cancers15205107.

A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.

Donnenberg V, Luketich J, Sultan I, Lister J, Bartlett D, Ghosh S Front Immunol. 2023; 14:1157697.

PMID: 37063842 PMC: 10097923. DOI: 10.3389/fimmu.2023.1157697.

References

. Postoperative empyema and survival in lung cancer. Br Med J. 1973; 1(5852):504-5. PMC: 1588733. DOI: 10.1136/bmj.1.5852.504-a. View

Addeo A, Friedlaender A, Giovannetti E, Russo A, de Miguel-Perez D, Arrieta O . A New Generation of Vaccines in the Age of Immunotherapy. Curr Oncol Rep. 2021; 23(12):137. PMC: 8566658. DOI: 10.1007/s11912-021-01130-x. View

Di Trani C, Fernandez-Sendin M, Cirella A, Segues A, Olivera I, Bolanos E . Advances in mRNA-based drug discovery in cancer immunotherapy. Expert Opin Drug Discov. 2021; 17(1):41-53. DOI: 10.1080/17460441.2021.1978972. View

Iacono A, Dauber J, Keenan R, Spichty K, Cai J, Grgurich W . Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation. 1997; 64(2):263-9. DOI: 10.1097/00007890-199707270-00015. View

Brombacher F, Kastelein R, Alber G . Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 2003; 24(4):207-12. PMC: 7141566. DOI: 10.1016/s1471-4906(03)00067-x. View

Edwards R, Gooding W, Lembersky B, Colonello K, Hammond R, Paradise C . Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol. 1997; 15(11):3399-407. DOI: 10.1200/JCO.1997.15.11.3399. View

Sterman D, Recio A, Carroll R, Gillespie C, Haas A, Vachani A . A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res. 2007; 13(15 Pt 1):4456-66. DOI: 10.1158/1078-0432.CCR-07-0403. View

Uciechowski P, Dempke W . Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020; 98(3):131-137. DOI: 10.1159/000505099. View

Donnenberg A, Luketich J, Dhupar R, Donnenberg V . Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer. 2019; 7(1):110. PMC: 6472034. DOI: 10.1186/s40425-019-0590-4. View

10.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

11.

Pennathur A, Abbas G, Christie N, Landreneau R, Luketich J . Video assisted thoracoscopic surgery and lobectomy, sublobar resection, radiofrequency ablation, and stereotactic radiosurgery: advances and controversies in the management of early stage non-small cell lung cancer. Curr Opin Pulm Med. 2007; 13(4):267-70. DOI: 10.1097/MCP.0b013e3281c61a85. View

12.

Clive A, Kahan B, Hooper C, Bhatnagar R, Morley A, Zahan-Evans N . Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014; 69(12):1098-104. PMC: 4251306. DOI: 10.1136/thoraxjnl-2014-205285. View

13.

Zamboni M, da Silva Jr C, Baretta R, Cunha E, Cardoso G . Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med. 2015; 15:29. PMC: 4379612. DOI: 10.1186/s12890-015-0025-z. View

14.

Hewitt S, Bailey D, Zielinski J, Apte A, Musenge F, Karp R . Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020; 26(23):6284-6298. DOI: 10.1158/1078-0432.CCR-20-0472. View

15.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

16.

Telvi L, Jaubert F, EYQUEM A, Andreux J, Labrousse F, CHRETIEN J . Study of immunoglobulins in pleura and pleural effusions. Thorax. 1979; 34(3):389-92. PMC: 471080. DOI: 10.1136/thx.34.3.389. View

17.

. Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000; 162(5):1987-2001. DOI: 10.1164/ajrccm.162.5.ats8-00. View

18.

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S . The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011; 1813(5):878-88. DOI: 10.1016/j.bbamcr.2011.01.034. View

19.

Dore P, Lelievre E, Morel F, Brizard A, Fourcin M, Clement C . IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases. Clin Exp Immunol. 1997; 107(1):182-8. PMC: 1904539. DOI: 10.1046/j.1365-2249.1997.d01-889.x. View

20.

Zeltsman M, Mayor M, Jones D, Adusumilli P . Surgical immune interventions for solid malignancies. Am J Surg. 2016; 212(4):682-690.e5. PMC: 5089080. DOI: 10.1016/j.amjsurg.2016.06.008. View